New guidelines on migraine prevention reflect increasing options for patients Since 2012, the FDA has approved a half dozen new medications By Isabella CuetoAug. 31, 2026 Chronic Disease Reporter

https://www.statnews.com/2026/08/31/migraine-prevention-medication-guidelines/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-_138aT13bjrzopKXIlbkM30g3rgHkB6i8ewiBQfvOB5U9t-5jaxxSOgtGICE_HhvKxCsrDypD_P7nG7nGe-mCXlMuF9g&_hsmi=436432001&utm_content=436432001&utm_source=hs_email New migraine guidelines highlight growing treatment options The American Headache Society and the American Academy of Neurology released new migraine guidelines yesterday, the first time they've done so since 2012. The groups gave high marks on efficacy and tolerability to AbbVie's Qulipta, Lundbeck's Vyepti, Amgen and Novartis' Aimovig, Teva's Ajovy, and Lilly's Emgality. They also recommended the drugs as a preventive option for patients who frequently rely on pain medication once their attacks begin. Some experts, however, were concerned that the new guidelines are complicated and may scare off primary care doctors.